Citations

Clear

3942 citation(s) found for "To, Van".

Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Sandau, Ursula S. , Magaña, Setty M. , Costa, Júlia , Nolan, John P. , Ikezu, Tsuneya , Vella, Laura J. , Jackson, Hannah K. , Palacio, Paola Loreto , Hill, Andrew F. , Keuren‐Jensen, Kendall Van , McFarland, Trevor J. , Palade, Joanna , Sribnick, Eric A. , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Saugstad, Julie A. , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task, Moreira, Lissette Retana , Hill, Andrew F , Quinn, Joseph F , Van Keuren-Jensen, Kendall R , McFarland, Trevor J , Sribnick, Eric A , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Yang, You , Falcón-Perez, Juan Manual , Nieuwland, Rienk , Saugstad, Julie A , Ikezu, Tsuneya , Quinn, Joseph F. , Palade, Joanna , You, Yang , Falcón‐Pérez, Juan Manuel , Nieuwland, Rienk , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task

Mayo Clinic

Journal of Extracellular Vesicles | December 29, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/jev2.12397 | PMID 38158550 Get It

Abstract Cerebrospinal fluid (CSF) is a clear, transparent fluid derived from blood plasma that protects the brain and spinal cord against mechanical shock, provides buoyancy, clears metabolic waste and transports extracellular components to remote sites in the brain. Given its contact with the brain and the spinal cord, CSF is the most informative biofluid for studies of the central nervous system (CNS). In addition to other components, CSF contains extracellular vesicles (EVs) that carry bioactive cargoes (e.g., lipids, nucleic acids, proteins), and that can have biological functions within and beyond the CNS. Thus, CSF EVs likely serve as both mediators of and contributors to communication in the CNS. Accordingly, their potential as biomarkers for CNS diseases has stimulated much excitement for and attention to CSF EV research. However, studies on CSF EVs present unique challenges relative to EV studies in other biofluids, including the invasive nature of CSF collection, limited CSF volumes and the low numbers of EVs in CSF as compared to plasma. Here, the objectives of the International Society for Extracellular Vesicles CSF Task Force are to promote the reproducibility of CSF EV studies by providing current reporting and best practices, and recommendations and reporting guidelines, for CSF EV studies. To accomplish this, we created and distributed a world‐wide survey to ISEV members to assess methods considered ‘best practices’ for CSF EVs, then performed a detailed literature review for CSF EV publications that was used to curate methods and resources. Based on responses to the survey and curated information from publications, the CSF Task Force herein provides recommendations and reporting guidelines to promote the reproducibility of CSF EV studies in seven domains: (i) CSF Collection, Processing, and Storage; (ii) CSF EV Separation/Concentration; (iii) CSF EV Size and Number Measurements; (iv) CSF EV Protein Studies; (v) CSF EV RNA Studies; (vi) CSF EV Omics Studies and (vii) CSF EV Functional Studies.
Exercise Catheterization in Adults Post-Fontan with Normal and Abnormal Haemodynamic Criteria: Insights Into Normal Fontan Physiology
Miranda, William R. , Jain, C. Charles , Connolly, Heidi M. , Bruaene, Alexander Van De , Egbe, Alexander C. , Borlaug, Barry A. , Burchill, Luke J.

Mayo Clinic

European Journal of Heart Failure | December 29, 2023 | Volume: 26 | Issue: 2 | Pages: 314-323

10.1002/ejhf.3119 | PMID 38155533 Get It

Abstract Aim The normal (i.e. expected) haemodynamics in adults post-Fontan remain poorly delineated. Moreover, the definitions of elevated exercise pulmonary artery (PA) and PA wedge pressure (PAWP) for this population have not been described. Methods and results Seventy-two adults post-Fontan undergoing exercise catheterization were categorized into abnormal (Group I, n = 59; defined as resting mean PA ≥14 mmHg and/or PAWP ≥12 mmHg, ΔPAWP/Δsystemic flow [Qs] >2 mmHg/L/min, and/or ΔPA/Δpulmonary flow >3 mmHg/L/min) and normal (Group II, n = 13) haemodynamics. Thirty-nine patients with non-cardiac dyspnoea (NCD) were included as controls. There was no difference in exercise arterial oxygen saturation (87% [81–92] vs. 89% [85–93], p = 0.29), while exercise PA pressure (27 [23–31] vs. 16 [14.5–19.5] mmHg, p < 0.001) and PAWP were higher (21 [18–28] vs. 12 [8–14] mmHg, p < 0.001) in Group I. At peak exercise, Group I had lower heart rate (97 [81–120] vs. 133 [112.5–147.5] bpm, p < 0.001) and Qs response (67.3 [43.8–93.1] vs. 105.9 (82–118.5) % predicted, p < 0.001) than Group II. Exercise superior vena cava pressures were higher (16 [14–22.5] vs. 5.5 [3–7.3] mmHg, p < 0.001) and arterial oxygen saturation lower (89% [85–93] vs. 97% [96–98], p < 0.001) in Group II compared to NCD, while no differences in PAWP, stroke volume index, heart rate, or Qs response were seen. If defined as two standard deviations above mean values for Group II, elevated PAWP and mean PA pressure post-Fontan would correspond to 20.6 mmHg and 25.8 mmHg, respectively. Conclusion PAWP >20 mmHg and mean PA pressure >25 mmHg could be used to define elevated values during exercise in adults post-Fontan. The major discrepancy in exercise haemodynamics among Group II compared to controls appears to be the degree of systemic venous hypertension and arterial desaturation.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Kyalwazi, Beverly , Campbell, Michael J. , Chien, A. Jo , Forero-Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Haley, Barbara , Clark, Amy S. , Nanda, Rita , Yung, Rachel L. , Tripathy, Debasish , Edmiston, Kristen K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Lu, Ruixiao , Symmans, W. Fraser , Yee, Douglas , Veer, Laura van ‘t , Esserman, Laura J. , Olopade, Olufunmilayo I. , Tripathy, Debu , Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , Yau, Christina , Yoshimatsu, Toshio F. , Wallace, Anne M. , Pusztai, Lajos , Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , DeMichele, Angela , Veer, Laura J. van’t

Mayo Clinic

JAMA Network Open | December 28, 2023 | Volume: 6 | Issue: 12 | Pages: e2349646

10.1001/jamanetworkopen.2023.49646 | PMID 38153734 Get It

ImportanceThere has been little consideration of genomic risk of recurrence by breast cancer subtype despite evidence of racial disparities in breast cancer outcomes.ObjectiveTo evaluate associations between clinical trial end points, namely pathologic complete response (pCR) and distant recurrence–free survival (DRFS), and race and examine whether gene expression signatures are associated with outcomes by race.Design, Setting, and ParticipantsThis retrospective cohort study used data from the Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 (I-SPY 2) multicenter clinical trial of neoadjuvant chemotherapy with novel agents and combinations for patients with previously untreated stage II/III breast cancer. Analyses were conducted of associations between race and short- and long-term outcomes, overall and by receptor subtypes, and their association with 28 expression biomarkers. The trial enrolled 990 female patients between March 30, 2010, and November 5, 2016, with a primary tumor size of 2.5 cm or greater and clinical or molecular high risk based on MammaPrint or hormone receptor (HR)-negative/ERBB2 (formerly HER2 or HER2/neu)–positive subtyping across 9 arms. This data analysis was performed between June 10, 2021, and October 20, 2022.ExposureRace, tumor receptor subtypes, and genomic biomarker expression of early breast cancer.Main Outcomes and MeasuresThe primary outcomes were pCR and DRFS assessed by race, overall, and by tumor subtype using logistic regression and Cox proportional hazards regression models. The interaction between 28 expression biomarkers and race, considering pCR and DRFS overall and within subtypes, was also evaluated.ResultsThe analytic sample included 974 participants (excluding 16 self-reporting as American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or multiple races due to small sample sizes), including 68 Asian (7%), 120 Black (12%), and 786 White (81%) patients. Median (range) age at diagnosis was 47 (25-71) years for Asian, 49 (25-77) for Black, and 49 (23-73) years for White patients. The pCR rates were 32% (n = 22) for Asian, 30% for Black (n = 36), and 32% for White (n = 255) patients (P = .87). Black patients with HR-positive/ERBB2-negative tumors not achieving pCR had significantly worse DRFS than their White counterparts (hazard ratio, 2.28; 95% CI, 1.24-4.21; P = .01), with 5-year DRFS rates of 55% (n = 32) and 77% (n = 247), respectively. Black patients with HR-positive/ERBB2-negative tumors, compared with White patients, had higher expression of an interferon signature (mean [SD], 0.39 [0.87] and −0.10 [0.99]; P = .007) and, compared with Asian patients, had a higher mitotic score (mean [SD], 0.07 [1.08] and −0.69 [1.06]; P = .01) and lower estrogen receptor/progesterone receptor signature (mean [SD], 0.31 [0.90] and 1.08 [0.95]; P = .008). A transforming growth factor β signature had a significant association with race relative to pCR and DRFS, with a higher signature associated with lower pCR and worse DRFS outcomes among Black patients only.Conclusions and RelevanceThe findings show that women with early high-risk breast cancer who achieve pCR have similarly good outcomes regardless of race, but Black women with HR-positive/ERBB2-negative tumors without pCR may have worse DRFS than White women, highlighting the need to develop and test novel biomarker-informed therapies in diverse populations.
AdipoRon reduces TGFβ1‐mediated collagen deposition in vitro and alleviates knee stiffness in vivo
Dudakovic, Amel , Limberg, Afton K. , Bothun, Cole E. , Dilger, Oliver B., Bayram, Banu , Bettencourt, Jacob W. , Thaler, Roman , Owen, Aaron R. , Iyer, Varun G., Payne, Ashley N. , Carstens, Mason F. , Wijnen, André J. van , Berry, Daniel J., Berry, Daniel J. , Carstens, Mason , Karczewski, Daniel C, Sanchez-Sotelo, Joaquin, Abdel, Matthew P , van Wijnen, Andre J , Berry, Daniel J , Salmons, Harold I. , Karczewski, Daniel , Payne, Ashley N., Berry, Daniel J., Sánchez‐Sotelo, Joaquín , Morrey, Mark E. , Abdel, Matthew P.

Mayo Clinic

Journal of Cellular Physiology | December 27, 2023 | Volume: 239 | Issue: 2 | Pages: No page available

10.1002/jcp.31168 | PMID 38149794 Get It

AbstractArthrofibrosis, which causes joint motion restrictions, is a common complication following total knee arthroplasty (TKA). Key features associated with arthrofibrosis include myofibroblast activation, knee stiffness, and excessive scar tissue formation. We previously demonstrated that adiponectin levels are suppressed within the knee tissues of patients affected by arthrofibrosis and showed that AdipoRon, an adiponectin receptor agonist, exhibited anti‐fibrotic properties in human mesenchymal stem cells. In this study, the therapeutic potential of AdipoRon was evaluated on TGFβ1‐mediated myofibroblast differentiation of primary human knee fibroblasts and in a mouse model of knee stiffness. Picrosirius red staining revealed that AdipoRon reduced TGFβ1‐induced collagen deposition in primary knee fibroblasts derived from patients undergoing primary TKA and revision TKA for arthrofibrosis. AdipoRon also reduced mRNA and protein levels of ACTA2, a key myofibroblast marker. RNA‐seq analysis corroborated the anti‐myofibrogenic effects of AdipoRon. In our knee stiffness mouse model, 6 weeks of knee immobilization, to induce a knee contracture, in conjunction with daily vehicle (DMSO) or AdipoRon (1, 5, and 25 mg/kg) via intraperitoneal injections were well tolerated based on animal behavior and weight measurements. Biomechanical testing demonstrated that passive extension angles (PEAs) of experimental knees were similar between vehicle and AdipoRon treatment groups in mice evaluated immediately following immobilization. Interestingly, relative to vehicle‐treated mice, 5 mg/kg AdipoRon therapy improved the PEA of the experimental knees in mice that underwent 4 weeks of knee remobilization following the immobilization and therapy. Together, these studies revealed that AdipoRon may be an effective therapeutic modality for arthrofibrosis.
PROGNOSTIC PERFORMANCE OF SERIAL DETERMINATION OF THE SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS SHOCK CLASSIFICATION IN ADULTS WITH CRITICAL ILLNESS
Sanghavi, Devang , Patel, Parag C. , Gajić, Ognjen, Jentzer, Jacob C. , Bhattacharyya, Anirban, Diepen, Sean van , Herasevich, Vitaly , Gajic, Ognjen , Kashani, Kianoush

Mayo Clinic

Shock | December 27, 2023 | Volume: 61 | Issue: 2 | Pages: 246-252

10.1097/shk.0000000000002292 | PMID 38150371 Get It

ABSTRACT Purpose: The aim of the study is to evaluate whether serial assessment of shock severity can improve prognostication in intensive care unit (ICU) patients. Materials and Methods: This is a retrospective cohort of 21,461 ICU patient admissions from 2014 to 2018. We assigned the Society for Cardiovascular Angiography and Interventions (SCAI) Shock Stage in each 4-h block during the first 24 h of ICU admission; shock was defined as SCAI Shock stage C, D, or E. In-hospital mortality was evaluated using logistic regression. Results: The admission SCAI Shock stages were as follows: A, 39.0%; B, 27.0%; C, 28.9%; D, 2.6%; and E, 2.5%. The SCAI Shock stage subsequently increased in 30.6%, and late-onset shock developed in 30.4%. In-hospital mortality was higher in patients who had shock on admission (11.9%) or late-onset shock (7.3%) versus no shock (4.3%). Persistence of shock predicted higher mortality (adjusted OR = 1.09; 95% CI = 1.06–1.13, for each ICU block with shock). The mean SCAI Shock stage had higher discrimination for in-hospital mortality than the admission or maximum SCAI Shock stage. Dynamic modeling of the SCAI Shock classification improved discrimination for in-hospital mortality (C-statistic = 0.64–0.71). Conclusions: Serial application of the SCAI Shock classification provides improved mortality risk stratification compared with a single assessment on admission, facilitating dynamic prognostication.
Natural cubic splines for the analysis of Alzheimer’s trials
Langford, Oliver , Dyck, Christopher H. van , Petersen, Ronald C. , Craft, Suzanne , Raman, Rema , Sims, John R. , Aisen, Paul , Donohue, Michael , Insel, Philip S. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S21 | Pages: No page available

10.1002/alz.070862 Get It

AbstractBackgroundMixed model repeated measures (MMRM) is the most common analysis approach in clinical trials for Alzheimer’s disease. The model treats time as a categorical variable, which can be problematic when assessments occur off‐schedule, as including off‐schedule visits can induce bias, and excluding them ignores valuable information and violates the intention to treat principle. This problem has been exacerbated by clinical trial visits which have been delayed due to the COVID19 pandemic. Since MMRM entails a mean parameter for each group and visit, the model can be inefficient for longer trials of Preclinical Alzheimer’s. As an alternative to MMRM, we propose a constrained longitudinal data analysis with natural cubic splines that treats time as continuous and uses test version effects to model the mean over time.MethodWe use model selection techniques to compare the predictive value of spline models to slope models, MMRM, and models that assume a proportional treatment effect using data from several completed trials. These trials include the ADCS trial of donepezil in MCI, trials of intranasal insulin and a fyn kinase inhibitor in mild Alzheimer’s dementia, and the A4 trial of solanezumab in Preclinical Alzheimer’s. Simulation studies assess the power and Type I error of these models for trials in Preclinical Alzheimer’s, MCI, and mild dementia.ResultThe spline model with ADAS‐Cog version effect attained the best predictive value for the trials in mild dementia. The proportional model was preferred for the trial in MCI, but the proportional effect assumption was violated, and the treatment effect estimate was in the wrong direction. Considering that the spline with two degrees of freedom and version effect provide fits that are similar to MMRM in Figure 1, we concluded that two degrees of freedom appear to be sufficient to capture enough of the general trend to assess the treatment effect. AIC results from the A4 Study will be considered and included after the study is completed in Spring 2023.ConclusionThe spline model is shown to have better predictive value and precision in real datasets and has better power and Type I error control in a variety of simulation scenarios.
Fluid Biomarkers for Neurobehavioral Dysregulation in Former American Football Players
Amerongen, Suzan van , Bernick, Charles , Alosco, Michael L. , Palmisano, Joseph , Tuz‐Zahra, Fatima , Balcer, Laura J. , Blennow, Kaj , Iliff, Jeffrey J. , Zetterberg, Henrik , Peskind, Elaine R. , Reiman, Eric M. , Pulukuri, Surya Vamsi , Tripodis, Yorghos , Geda, Yonas E. , Wethe, Jennifer V. , Katz, Douglas I. , Mez, Jesse , Adler, Charles H. , Ashton, Nicholas J. , Li, Ge , Shenton, Martha E. , Cummings, Jeffrey L. , Stern, Robert A.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S17 | Pages: No page available

10.1002/alz.077858 Get It

AbstractBackgroundThe NINDS criteria define Traumatic Encephalopathy Syndrome (TES) as the clinical manifestation of the neuropathologically diagnosed chronic traumatic encephalopathy (CTE). The core clinical features of TES include both cognitive and neuropsychiatric symptoms, the latter termed neurobehavioral dysregulation (NBD). We explored potential biological correlates of NBD by investigating fluid biomarkers of neuronal damage, astrogliosis, phosphorylated tau (pTau), neuroinflammation, and catecholamines in former American football players.MethodOur cohort consisted of former professional (PRO) and college (COL) American football players from the DIAGNOSE CTE Research Project. NBD was measured by four subscales (i.e., explosivity, emotional dyscontrol, impulsivity, affective lability) and a total NBD score, derived by factor analysis of multiple self‐report neuropsychiatric measures. Plasma neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), CSF total tau and pTau181/231/217, as well as CSF biomarkers related to neuroinflammation (IL‐6, CRP, TNF‐α, VEGF‐A), were measured with various well‐validated immunoassay methods. Catecholamines in CSF (dopamine, 3,4‐dihydroxyphenylacetic acid, 3,4‐dihydroxyphenylalanine, noradrenaline, 3,4‐dihydroxyphenylglycol) were measured with HPLC. Multivariate linear regression models assessed the relationships between biomarkers and NBD scales, adjusted for age, BMI, race, and APOE e4, including stratification by exposure group, i.e., PRO, COL.ResultDemographics and biomarker levels are displayed in Table 1. High levels of IL‐6 were significantly associated with higher scores of all NBD subscales, independent of exposure group. Other significant relationships included plasma NfL with emotional dyscontrol and impulsivity. Within the college group, CSF pTau181 was significantly associated with emotional dyscontrol and CSF noradrenaline with explosivity, emotional dyscontrol, impulsivity, and total NBD score. (Table 2 & Figure 1). IL‐6 models were repeated with measures of cognitive dysfunction (another core feature of TES) added as covariates; these analyses again found significant relationships between IL‐6 and NBD, irrespective of cognitive functioning.ConclusionWe observed specific fluid biomarkers related to NBD in former American football players. Of note were the associations between IL‐6 and all NBD subscales (and not with cognitive functioning), suggesting that neuroinflammation may be a specific component in the expression of NBD symptoms. Future studies will investigate how these neuroinflammatory processes are related to other biomarkers, level of RHI exposure, and neuropathology.
CONCORDANCE BETWEEN VISUAL INTERPRETATION AND QUANTITATIVE ANALYSIS OF [18F]FLORTAUCIPIR PET IMAGES
Raghavan, Sheelakumari , Sparrman, Kohl Johnson, Costoya‐Sánchez, Alejandro , Mainta, Isminni, Devous, Michael D. , Pontecorvo, Michael J. , Petersen, Ronald C. , Rial, Alexis Moscoso , Heeman, Fiona , Camacho, Valle , Essen, Martijn van , Grothe, Michel J. , Ribaldi, Federica , Frisoni, Giovanni B. , Garibotto, Valentina , Jack, Clifford R. , Vemuri, Prashanthi , Schöll, Michael

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S16 | Pages: No page available

10.1002/alz.080433 Get It

AbstractBackgroundPositron emission tomography (PET) imaging with [18F]flortaucipir allows for in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). The FDA‐approved label for [18F]flortaucipir PET provides a standardized, clinically applicable definition of tau‐PET positivity by visual interpretation. Here, we studied the concordance between this visual interpretation and quantitative approaches employed in research.MethodWe included 2692 participants (cognitively unimpaired [CU] and impaired [CI, MCI or AD dementia]) from four cohorts (Mayo Clinic Study of Aging and ADRC, ADNI, A4, and A05) with available [18F]flortaucipir PET (mean age: 70.2 y, 50.0% females). Three trained readers assessed each [18F]flortaucipir PET scan according to the FDA‐approved method. Visual reads were compared to an established approach for defining tau‐PET positivity based on SUVR values in a temporal meta‐ROI (Jack, et al. Alzheimers Dement. 2017). Previously defined “lenient” (SUVR = 1.22) and “conservative” (SUVR = 1.30) cut‐points were explored. In addition, visual reads were compared to tau‐PET positivity as defined by a scheme based on the expected spatial progression of tau pathology from the medial temporal lobe (MTL) to the temporal neocortex (NEO) (Ossenkoppele, et al. Nat Med. 2022; cut‐points: SUVRMTL = 1.30, SUVRNEO = 1.37).ResultConcordance between visual and quantitative approaches was limited (Figure 1): the “lenient” and MTL‐NEO methods yielded high rates of quantitative‐positive, visual‐negative scans (73‐52% and 26‐18% for CU and CI, respectively), while the “conservative” cut‐point failed to detect 45% and 13% of the CU and CI visual‐positive scans, respectively. The prevalence of tau‐PET positivity in Aβ‐negative individuals was highest with the “lenient” cut‐point (∼24%) and lowest with visual interpretation (∼3%) (Figure 2). Visual‐positive, quantitative‐negative individuals were more frequently Aβ‐positive than visual‐negative, quantitative‐positive individuals (“lenient”: 86% vs 50%, p<0.001; “conservative”: 87% vs 58%, p<0.001; MTL‐NEO: 85% vs 70%, p = 0.005). Among visually‐positive participants, 164 (28%) showed a tau deposition pattern that deviated from the expected MTL to NEO progression (Figure 3).ConclusionVisual and quantitative methods for [18F]flortaucipir PET are non‐exchangeable. Tau‐PET positivity based on visual interpretation aligns better with Aβ‐pathology. A significant number of visually‐positive participants showed a pattern of tau accumulation that deviated from the expected stereotypical spatial progression and was not detected by standard quantitative methods.
White matter hyperintensities associate with pathological stages of neurodegenerative disease.
Lin, Chen‐Pei , Bouwman, Maud M.A. , Reijner, Niels , Steenwijk, Martijn D. , Jonkman, Laura E. , Frigerio, Irene , Noteboom, Samantha , Preziosa, Paolo , Boon, Baayla D.C. , Bouwman, Femke H. , Rozemüller, Annemieke J.M. , Barkhof, Frederik , Berg, Wilma D. J. van de

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.079560 Get It

AbstractBackgroundWhite matter hyper‐intensities (WMH) are observed on FLAIR MRI, increase with age and are more prominent in neurodegenerative diseases such as in Alzheimer’s disease (AD) and Parkinson’s disease (PD). The aim of this study was to assess the association between WMH and neuropathological staging of amyloid‐beta, neurofibrillary tangles (NFT) and α‐synuclein (α‐syn).MethodIn‐situ 3T‐MRI 3DT1‐weighted and 3D‐FLAIR data were collected for 77 clinically defined and pathologically‐confirmed brain donors; 31 AD, 21 PD and PD dementia (PDD), and 25 controls. WMH were segmented on FLAIR using an in‐house developed multiview convolutional neural network, followed by manual checking, and volume was obtained with FSL. Fifteen brain regions were dissected at autopsy, immunostained and evaluated for neuropathological diagnosis, including Thal amyloid phase, CAA type, and Braak stages for NFT and α‐syn. Group differences were assessed with linear models (corrected for age, gender, post‐mortem delay), and associations with Spearman and Pearson partial correlations.ResultCompared to controls, WMH load was higher in AD (p<0.001), specifically amnestic AD (p = 0.003) rather than non‐amnestic AD (p = 0.053), and higher in PD (p = 0.016), specifically non‐demented PD (p = 0.015) rather than PDD (p = 1.0). No difference in gender was observed (p = 0.38). Without the influence of pathology (in controls), WMH was associated with age (r = 0.49,p = 0.016).In the whole cohort, WMH was associated with Fazekas score (r = 0.67; p<0.001), normalized brain volume (NBV; r = ‐0.31,p = 0.007), gray matter volume (NGMV; r = ‐0.36,p = 0.002), Thal phase (r = 0.24,p0.034), Braak NFT stage (r = 0.33,p = 0.004), and Braak α‐syn stage (r = 0.27, p0.018).Across controls and AD, WMH associated with NBV (r = ‐0.39,p = 0.004), NGMV (r = ‐0.42,p = 0.002), left and right hippocampal volume (r = ‐0.36,p = 0.008 and r = ‐0.32,p = 0.022), Braak NFT (r = 0.41,p<0.001), Thal phase (r = 0.41,p = 0.002), and CAA (r = 0.34,p = 0.01). Amnestic and non‐amnestic AD showed similar results, except for CAA, which was associated with WMH in non‐amnestic AD only (r = 0.33,p = 0.04).Across controls and PD(D), WMH associated with Braak NFT stage (r = 0.39,p = 0.008) and Braak α‐syn stage (r = 0.60,p<0.001), but not with MRI outcome measures. In this respect PD and PDD showed different results; in PD WMH associated with NGMV (r = ‐0.37,p = 0.031), in PDD with left and right hippocampal volume (r = ‐0.44,p = 0.014 and r = ‐0.44,p = 0.015).ConclusionWMH associate with pathological stages of AD and PD(D), and contributes to MRI atrophy.
Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir pet images
Raghavan, Sheelakumari , Sparrman, Kohl Johnson, Costoya‐Sánchez, Alejandro , Mainta, Isminni, Devous, Michael D. , Pontecorvo, Michael J. , Petersen, Ronald C. , Rial, Alexis Moscoso , Heeman, Fiona , Camacho, Valle , Essen, Martijn van , Grothe, Michel J. , Ribaldi, Federica , Frisoni, Giovanni B. , Garibotto, Valentina , Jack, Clifford R. , Vemuri, Prashanthi , Schöll, Michael

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.082007 Get It

AbstractBackgroundPositron emission tomography (PET) imaging with [18F]flortaucipir allows for in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). The FDA‐approved label for [18F]flortaucipir PET provides a standardized, clinically applicable definition of tau‐PET positivity by visual interpretation. Here, we studied the concordance between this visual interpretation and quantitative approaches employed in research.MethodWe included 2692 participants (cognitively unimpaired [CU] and impaired [CI, MCI or AD dementia]) from four cohorts (Mayo Clinic Study of Aging and ADRC, ADNI, A4, and A05) with available [18F]flortaucipir PET (mean age: 70.2 y, 50.0% females). Three trained readers assessed each [18F]flortaucipir PET scan according to the FDA‐approved method. Visual reads were compared to an established approach for defining tau‐PET positivity based on SUVR values in a temporal meta‐ROI (Jack, et al. Alzheimers Dement. 2017). Previously defined “lenient” (SUVR = 1.22) and “conservative” (SUVR = 1.30) cut‐points were explored. In addition, visual reads were compared to tau‐PET positivity as defined by a scheme based on the expected spatial progression of tau pathology from the medial temporal lobe (MTL) to the temporal neocortex (NEO) (Ossenkoppele, et al. Nat Med. 2022; cut‐points: SUVRMTL = 1.30, SUVRNEO = 1.37).ResultConcordance between visual and quantitative approaches was limited (Figure 1): the “lenient” and MTL‐NEO methods yielded high rates of quantitative‐positive, visual‐negative scans (73‐52% and 26‐18% for CU and CI, respectively), while the “conservative” cut‐point failed to detect 45% and 13% of the CU and CI visual‐positive scans, respectively. The prevalence of tau‐PET positivity in Aß‐negative individuals was highest with the “lenient” cut‐point (∼24%) and lowest with visual interpretation (∼3%) (Figure 2). Visual‐positive, quantitative‐negative individuals were more frequently Aß‐positive than visual‐negative, quantitative‐positive individuals (“lenient”: 86% vs 50%, p<0.001; “conservative”: 87% vs 58%, p<0.001; MTL‐NEO: 85% vs 70%, p = 0.005). Among visually‐positive participants, 164 (28%) showed a tau deposition pattern that deviated from the expected MTL to NEO progression (Figure 3).ConclusionVisual and quantitative methods for [18F]flortaucipir PET are non‐exchangeable. Tau‐PET positivity based on visual interpretation aligns better with Aß‐pathology. A significant number of visually‐positive participants showed a pattern of tau accumulation that deviated from the expected stereotypical spatial progression and was not detected by standard quantitative methods.